Celcuity Inc. (CELC)
NASDAQ: CELC · Real-Time Price · USD
44.24
+0.05 (0.11%)
Aug 7, 2025, 4:00 PM - Market closed
Celcuity Employees
Celcuity had 87 employees as of December 31, 2024. The number of employees increased by 32 or 58.18% compared to the previous year.
Employees
87
Change (1Y)
32
Growth (1Y)
58.18%
Revenue / Employee
n/a
Profits / Employee
-$1,461,656
Market Cap
1.80B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 87 | 32 | 58.18% |
Dec 31, 2023 | 55 | 10 | 22.22% |
Dec 31, 2022 | 45 | 6 | 15.38% |
Dec 31, 2021 | 39 | 9 | 30.00% |
Dec 31, 2020 | 30 | 3 | 11.11% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
CELC News
- 1 day ago - Celcuity Inc. Schedules Release of Second Quarter 2025 Financial Results and Webcast/Conference Call - GlobeNewsWire
- 8 days ago - Celcuity: Positive Phase 3 Wild-Type ABC Data With Gedatolisib Leads To End Of 2025 Catalyst - Seeking Alpha
- 9 days ago - Celcuity Inc. Announces Pricing of Concurrent Public Offerings of 2.750% Convertible Senior Notes Due 2031 and Common Stock and Pre-Funded Warrants - GlobeNewsWire
- 10 days ago - Celcuity: What's Happening With CELC Stock? - Forbes
- 10 days ago - Celcuity Inc. Announces Concurrent Public Offerings of Convertible Senior Notes Due 2031 and Common Stock - GlobeNewsWire
- 10 days ago - Celcuity shares skyrocket as breast cancer drug combo shows dramatic Phase 3 success - Invezz
- 11 days ago - Celcuity's triple cancer drug combo tops AstraZeneca's in cutting progression in study - Reuters
- 11 days ago - Celcuity Announces Clinically Meaningful Improvement in Both Progression-Free Survival (“PFS”) Primary Endpoints from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Trial - GlobeNewsWire